How it works
How Much Does Immunotherapy for prostate cancer Cost in Spain?
Immunotherapy for prostate cancer in Spain typically costs from $6,000 to $18,000. The final price depends on the specific drug type, treatment duration, and required cycles. Patients save around 84% compared to the US, where this procedure costs $76,500 on average. Standard Spanish protocols usually include initial specialist consultations, drug administration, and routine monitoring during the therapy. Barcelona and Madrid remain the primary medical hubs for these advanced oncological treatments.
- Specific drug therapies: Cost variations depend on whether using Pembrolizumab or dendritic cell vaccines.
- Treatment cycles: The number of infusions required for the specific clinical case impacts total fees.
- Diagnostic assessments: Pre-treatment PSMA PET-CT scans can add approximately 15-20% to the initial budget.
- Monitoring programs: Extended six-month observation periods involve additional costs for specialist follow-up and imaging.
Bookimed Expert Insight: Spain offers a unique balance of high-tier clinical care and lower medication premiums. Centro Médico Teknon in Barcelona is a Joint Commission International (JCI) accredited facility with 400 specialized doctors. It is often chosen by high-profile international figures for its discretion and 5-star service. Hospital HM Nou Delfos provides access to one of the largest medical networks in Spain. Patients can access advanced radiotherapy units and urological expertise at competitive European rates. Choosing these established centers often secures better inclusive pricing for integrated diagnostic and treatment packages.
| Turkey | Austria | Spain | |
|---|---|---|---|
| Immunotherapy for prostate cancer | from $8,000 | ≈ $9,500 | from $6,000 |
Discover the Best Immunotherapy for prostate cancer Clinics in Spain: 4 Verified Options and Prices
Centro Médico Teknon
Joan Carles Galceran








Hospital HM Nou Delfos
Begona Mellado Gonzalez



GenesisCare Clinics
Immunotherapy for prostate cancer Overview in Spain
- Biological therapy - from $900This therapy uses living organisms to treat disease by stimulating the body"s own immune system.
- Immunotherapy - from $3,500This therapy boosts the body"s natural defenses to fight diseases like cancer, bringing less side effects.
- Immunotherapy with Keytruda (Pembolizumab) - from $13,500The therapy is a treatment enhancing the body"s immune system to fight cancer, using a drug highly targeted and effective.
- Immunotherapy for prostate cancer - from $6,000This therapy boosts the body"s immune system to fight against prostate cancer, offering a targeted, typically well-tolerated treatment.
- Immunotherapy for lung cancer - from $5,000This therapy boosts your body"s natural defenses to fight lung cancer, using substances made by the body itself.
- Immunotherapy for breast cancer - from $2,200This therapy boosts your immune system to fight and eradicate breast cancer cells effectively.
- Immunotherapy for kidney cancer - from $2,200This therapy boosts the body"s natural defenses, often prolonging life in kidney cancer patients.
- Sarcoma Immunotherapy - from $6,000This therapy boosts the body"s immune system to fight cancerous tumors, offering promising, targeted treatment for sarcoma.
Day 1
- Arrive at the medical facility for check-in.
- Meet with the oncologist for a consultation.
- Undergo necessary blood tests.
Day 2
- Get results from the blood tests.
- Prepare for the Immunotherapy treatment.
Day 3
- Begin the Immunotherapy treatment.
- The process takes about 3 hours.
- No anesthesia is required for this procedure.
Day 4
- Post-treatment consultation with the oncologist.
- Stay in the clinic for observation.
Week 1
- Start of the recovery period.
- Regular follow-up with the oncologist.
- Start light physical activities.
Week 2
- Progress to moderate physical activities.
- Continue the regular follow-up with the oncologist.
Week 3
- Return to work and other daily activities.
- Follow-up with the oncologist for progress check.
Week 4
- Resume sports and other strenuous activities.
- Continue regular follow-up with the oncologist.
Please note that each patient"s experience with Immunotherapy for prostate cancer can vary. The above timeline provides a general guideline but individual cases may differ.
- Bookimed deposit: $200 or €200.
- Clinic deposit: Pay a set percentage in advance.
Our Doctors
View all Doctors
Joan Carles Galceran
Dr. Joan Carles Galceran is a medical oncologist at the JCI-accredited Teknon Medical Center. He heads the Genitourinary and Sarcoma Unit at Vall d'Hebron University Hospital. Dr. Galceran specializes in non-surgical treatments for prostate, kidney, and bladder cancers. He is recognized as a top Spanish expert in genitourinary oncology.
- Authored over 120 peer-reviewed articles on new cancer therapeutic agents.
- Former Vice-President of the Spanish Group for the Treatment of Genitourinary Tumors.
- Serves as an advisor for the Catalan Health Service oncology guidelines.
- Led numerous national multicenter clinical trials for immunotherapy and angiogenesis.

Begona Mellado Gonzalez
Dr. Begona Mellado Gonzalez is a senior oncologist specializing in urological cancers at Hospital HM Nou Delfos. She has published over 140 scientific articles in international journals. Dr. Mellado Gonzalez completed a post-doctoral stay at Memorial Sloan-Kettering Cancer Center in New York. She serves as a leading researcher for prostate cancer at the IDIBAPS institute.
- Expertise in prostate, kidney, bladder, and testicular cancer treatment.
- Acts as principal investigator for multiple Phase I–III clinical trials.
- Winner of the extraordinary prize for her doctoral thesis at the University of Barcelona.
- Directs postgraduate urological cancer programs as an associate professor.
Video Stories from Bookimed Patients
Reviews about Bookimed: Discover Patients' Insights
All reviews


Share this content
Anna Leonova
FAQ about Immunotherapy for prostate cancer in Spain
What types of immunotherapy are available for prostate cancer in Spain in 2026?
Immunotherapy for prostate cancer in Spain focuses on checkpoint inhibitors, cellular vaccines, and clinical trials for advanced cases. Current options include PD-1 and CTLA-4 blockers, cancer treatment vaccines like Sipuleucel-T, and emerging personalized mRNA-based therapies provided at Joint Commission International-accredited centers in Madrid and Barcelona.
- Checkpoint inhibitors: PD-1 and CTLA-4 blockers target pathways to help immune cells attack tumors.
- Cancer vaccines: Personalized Sipuleucel-T trains immune cells to recognize prostate-specific proteins in metastatic cases.
- Experimental therapies: Clinics offer mRNA-based vaccines and CCR5 expression targeting through advanced clinical trials.
- Cost structure: Specialized treatment costs range from $6,000 to $18,000 at leading Spanish hospitals.
Bookimed Expert Insight: Spain ranks among the top 5 destinations globally for oncology in our network. Patients often find better value at large networks like HM Hospitals. Their facilities maintain high Joint Commission International standards while offering costs approximately 84% lower than US averages.
Patient Consensus: Spain is a recognized hub for experimental cancer research. Patients often seek access to early-stage clinical trials here when seeking the latest immunological developments not yet widely available.
Does immunotherapy work for all prostate cancer patients?
Immunotherapy does not work for all prostate cancer patients because these tumors are typically immunologically cold. Success depends on specific genetic markers like high microsatellite instability (MSI-H). Standard drugs like Pembrolizumab only show a 5% to 17% response rate in metastatic cases.
- Biomarker requirements: Eligibility often requires high tumor mutational burden or DNA mismatch repair deficiency.
- Cold tumor environment: Prostate tumors lack sufficient lymphocytes to trigger a strong immune response.
- Specific approvals: Therapies like Sipuleucel-T provide modest survival gains rather than total growth arrest.
- Genetic testing: Oncologists in Spain prioritize genetic profiling to identify the few eligible candidates.
Bookimed Expert Insight: Spain ranks 5th globally for oncology requests, with centers like Centro Médico Teknon handling 10,000 patients annually. While immunotherapy costs $6,000 to $18,000 here, it is rarely the first choice. Data shows surgeons often prioritize advanced robotics like Da Vinci Xi at Hospital Ruber Internacional before considering systemic immune treatments.
Patient Consensus: Many patients find these treatments are not a one-size-fits-all solution and require specific mutations to be effective. Research suggests checking clinical registries rather than assuming eligibility for late-stage cases.
Can I get Pembrolizumab (Keytruda) for prostate cancer in Spain?
Patients can access Pembrolizumab (Keytruda) for prostate cancer in Spain, primarily for advanced metastatic cases showing specific genetic markers like high microsatellite instability. Access generally requires a prescription from an oncologist at JCI-accredited facilities and is often managed through clinical trials or specialized combination protocols.
- Biomarker requirements: Treatment is prioritized for patients with high PD-L1 expression or microsatellite instability.
- Clinical access: Specialists at Centro Médico Teknon often provide access through experimental or trial-based protocols.
- Administration method: Medication is delivered via intravenous infusion within specialized oncology departments or centers.
- Treatment alternatives: Patients frequently evaluate Lutetium-177 (Lu-177) therapy when immunotherapy is not clinically indicated.
Bookimed Expert Insight: Spain ranks among the top 5 global destinations for oncology on Bookimed, largely due to high-volume centers like Hospital HM Nou Delfos. While immunotherapy for prostate cancer is priced between $6,000 and $18,000, this often includes advanced molecular profiling that isn't standard elsewhere.
Patient Consensus: Patients note that Keytruda is rarely approved for standard adenocarcinoma cases without specific mutations. Many suggest adopting a high-fiber diet to potentially improve the immune response during treatment.
Is immunotherapy covered by the Spanish Public Health System (SNS)?
Immunotherapy is covered by the Spanish Public Health System (SNS) when authorized by the Spanish Agency of Medicines and Medical Devices (AEMPS). Coverage includes advanced therapies like CAR T-cell treatments and specific drugs evaluated for clinical efficacy, safety, and cost-effectiveness within the public hospital network.
- Regulatory approval: The AEMPS determines which drugs receive public funding based on rigorous clinical evaluation.
- Regional access: Availability may vary slightly between Spains seventeen Autonomous Communities (AACC) despite national mandates.
- Treatment scope: Public coverage includes approved drugs for specific indications, like Keytruda or Opdivo.
- Private alternatives: Non-covered patients find private cycles cost $3,500 to $18,000 in Spain.
Bookimed Expert Insight: Spain attracts 25,000+ patients annually to centers like Hospital Ruber Internacional due to high technology density. While the public system covers citizens, international patients often choose JCI-accredited clinics in Barcelona or Madrid. These private facilities offer rapid access to prostate cancer immunotherapy for $6,000 to $18,000, which is roughly 84% less than US averages.
Patient Consensus: Patients emphasize consulting a local oncologist to verify if specific protocols are included in public healthcare. Many explore clinical trials through the Spanish health system when standard immunotherapy coverage is not yet applicable.
Which hospitals in Spain offer advanced prostate cancer immunotherapy?
Top JCI-accredited hospitals in Madrid and Barcelona offer advanced immunotherapy for prostate cancer, providing specialized treatments like Lu-177 PSMA radioligand therapy. Notable institutions include Hospital Ruber Internacional, Centro Médico Teknon, and Hospital HM Nou Delfos, where multidisciplinary tumor boards coordinate precision oncology and surgical interventions.
- Available technologies: Centers utilize CyberKnife, Da Vinci Xi robotics, and advanced tomotherapy for targeted treatment.
- Accredited facilities: Hospital Ruber Internacional and Centro Médico Teknon maintain Joint Commission International (JCI) accreditation.
- Geographic hubs: Major oncology centers are concentrated in Madrid and Barcelona, serving 10,000+ patients annually.
- Specialized expertise: Clinics feature multidisciplinary teams focusing on medical-surgical oncology and uro-oncology research.
Bookimed Expert Insight: Spain ranks 5th globally for oncology requests, largely due to high-volume centers like Hospital HM Nou Delfos, which sees 400,000 patients yearly. While traditional immunotherapy costs $6,000 to $18,000, patients should verify if their case requires Lu-177 PSMA, a common advanced alternative in Spanish clinical practice.
Patient Consensus: Patients emphasize undergoing a PET-PSMA scan before selecting a facility to ensure accurate staging. Experts recommend prioritizing hospitals with multidisciplinary tumor boards and seeking second opinions from recognized centers of excellence.
How can I access immunotherapy clinical trials in Spain?
Accessing immunotherapy clinical trials in Spain requires registration through the Spanish Clinical Trials Registry (REEC) or a direct referral to JCI-accredited oncology hubs like Centro Médico Teknon or Hospital Ruber Internacional. Specialized centers utilize genomic profiling to match patients with phase I-III experimental systemic therapies.
- Physician referral: Get a specialized referral to high-activity centers like START Madrid-Fundación Jiménez Díaz.
- Genomic profiling: Request comprehensive genetic testing to meet strict biomarker-driven enrollment criteria.
- Official registry: Search the AEMPS-managed REEC database for authorized immunotherapy studies in Spain.
- Specialized consults: Contact international patient desks at Hospital HM Nou Delfos for screening assistance.
Bookimed Expert Insight: Spain ranks among the top 10 global destinations for clinical research, yet trial accessibility often depends on clinic network size. Choosing a facility like Hospital HM Nou Delfos, which is part of Spain's largest medical network, provides broader access to multi-center trials that smaller hospitals may not offer.
Patient Consensus: Patients emphasize the need to challenge standard protocols and proactively request second opinions if initial trial enrollment is dismissed. They suggest inquiring directly about early-phase trials that have shown high remission rates for specific genomic profiles.
Are there any new, groundbreaking trials for prostate cancer in Spain this year?
Spain is hosting pioneering prostate cancer trials this year focused on precision medicine and immune system modulation. Key studies include the Teverelix Phase 2b trial for high cardiovascular risk patients and the CHAMP trial, which combines dual immunotherapy with chemotherapy for aggressive neuroendocrine variants.
- Precision therapy: The Teverelix study offers safer hormone options for patients with cardiac concerns.
- Treatment intensification: PROTEUS trials combine apalutamide with surgery to improve metastasis-free survival rates.
- Immune modulation: Research targeting SOS signals aims to restore sensitivity to medications like enzalutamide.
- Top centers: Trials are active at Vall dHebron Institute and Hospital Clinic de Barcelona.
Bookimed Expert Insight: While many focus on Madrid, Barcelona's Centro Medico Teknon and HM Nou Delfos serve over 410,000 patients annually. This massive volume makes these centers primary hubs for Phase 1 and 2 immunotherapy trials that are often unavailable in smaller European regions.
Patient Consensus: Patients emphasize the importance of distinguishing between adjunct experimental drugs and standard protocols. Many suggest contacting major oncology centers directly to verify if early trial successes in complete remission apply to their specific cancer stage.





